Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul-Aug;137(4):695-701.
doi: 10.1177/00333549211018679. Epub 2021 May 26.

Characteristics of Adults Who Use Both Marijuana and E-Cigarette, or Vaping, Products: A Cross-Sectional Study, Utah, 2018

Affiliations

Characteristics of Adults Who Use Both Marijuana and E-Cigarette, or Vaping, Products: A Cross-Sectional Study, Utah, 2018

Nathaniel M Lewis et al. Public Health Rep. 2022 Jul-Aug.

Abstract

Objectives: Among young people, dual use of marijuana and e-cigarette, or vaping, products (EVPs) is linked with using more inhalant substances and other substances, and poorer mental health. To understand antecedents and potential risks of dual use in adults, we analyzed a representative adult population in Utah.

Methods: We used data from the 2018 Utah Behavioral Risk Factor Surveillance System (n = 10 380) and multivariable logistic regression to evaluate differences in sociodemographic characteristics, comorbidities, and risk factors among adults aged ≥18 who reported currently using both EVPs (any substance) and marijuana (any intake mode), compared with a referent group of adults who used either or neither.

Results: Compared with the referent group, adults using EVPs and marijuana had greater odds of being aged 18-29 (adjusted odds ratio [aOR] = 12.44; 95% CI, 6.15-25.14) or 30-39 (aOR = 3.75; 95% CI, 1.73-8.12) versus ≥40, being male (aOR = 3.29; 95% CI, 1.82-5.96) versus female, reporting ≥14 days of poor mental health in previous 30 days (aOR = 2.30; 95% CI, 1.23-4.32) versus <14 days, and reporting asthma (aOR = 2.09; 95% CI, 1.02-4.31), chronic obstructive pulmonary disorder (aOR = 2.94; 95% CI, 1.19-7.93), currently smoking cigarettes (aOR = 4.56; 95% CI, 2.63-7.93), or past-year use of prescribed chronic pain medications (aOR = 2.13; 95% CI, 1.06-4.30), all versus not.

Conclusions: Clinicians and health promotion specialists working with adults using both EVPs and marijuana should assess risk factors and comorbidities that could contribute to dual use or associated outcomes and tailor prevention messaging accordingly.

Keywords: EVALI; cross-sectional study; e-cigarettes; marijuana; pulmonary injury; vaping.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Similar articles

Cited by

References

    1. Creamer MR., Wang TW., Babb S. et al.. Tobacco product use and cessation indicators among adults—United States, 2018. MMWR Morb Mortal Wkly Rep. 2019;68(45):1013-1019.10.15585/mmwr.mm6845a2 - DOI - PMC - PubMed
    1. Wang TW., Gentzke AS., Creamer MR. et al.. Tobacco product use and associated factors among middle and high school students—United States, 2019. MMWR Surveill Summ. 2019;68(12):1-22.10.15585/mmwr.ss6812a1 - DOI - PMC - PubMed
    1. Utah Department of Health . Complete health indicator report of electronic cigarettes/vape products. November 20, 2020. Accessed April 15, 2021. https://ibis.health.utah.gov/ibisph-view/indicator/complete_profile/ECig...
    1. Temple JR., Shorey RC., Lu Y., Torres E., Stuart GL., Le VD. E-cigarette use of young adults: motivations and associations with combustible cigarette, alcohol, marijuana, and other illicit drugs. Am J Addict. 2017;26(4):343-348.10.1111/ajad.12530 - DOI - PMC - PubMed
    1. Trivers KF., Gentzke AS., Phillips E., Tynan M., Marynak KL., Schauer GL. Substances used in electronic vapor products among adults in the United States, 2017. Addict Behav Rep. 2019;10:100222.10.1016/j.abrep.2019.100222 - DOI - PMC - PubMed

LinkOut - more resources